<DOC>
	<DOC>NCT02373462</DOC>
	<brief_summary>To study the effect of olmesartan on walking distance and quality of life in peripheral artery disease patients with hypertension treated For intermittent claudication.</brief_summary>
	<brief_title>Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Aged between 20 and 85 years at visit 1 Patients with anklebrachial index (ABI) of less than 0.9 in one or both legs with history of intermittent claudication stable for the previous 6 months Patients whose statins, anti hypertensive medications and antiplatelet medications are stable for the past 6 months. Statins and cilostazol are allowed but needs to be stable for the past 6 months (diabetic medications may be changed) Patients whose blood pressure is more than 140/90 mmHg with/without antihypertension treatment Blood pressure of more than 180/110 mmHg Patients taking ARBs or ACE inhibitors treatment for at least 6 months before Patients taking aldosterone receptor antagonists at least 6 months before Patients with serum creatinine of more than 3 mg/dL serum potassium (K+) &gt; 5.5mg/dl History of bilateral renal artery stenosis History of acute coronary syndrome or heart failure hospitalization within 6 months Peripheral arterial revascularization planned within 1 month Critical limb ischemia Patients with impaired cognition (e.g. dementia) pregnancy or women at age of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>